In a research note released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN) and a $65 price target, which represents …
In a research note published today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on Alexion Pharmaceuticals (ALXN) with a $162 price …
In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals (AEGR) with a $90 price target, which …
In a research report issued yesterday, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following data release from …
In a research note issued today, Janney Capital analyst Kimberly Lee upgraded shares of Amicus Therapeutics (FOLD) from Hold to Buy and raised her price target to …
In a research note released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Cell Therapeutics Inc. (CTIC) with a $4 fair value estimate, …
